Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neuroscience

• Publication date

  2006-05-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NEUROSCIENCE.2005.12.042PMID 16483723PMCID PMC1464838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

  2006cited by this paper
• Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

  2006cited by this paper
• Subcellular Localization of Cyclic Nucleotide Phosphodiesterase Type 10A Variants, and Alteration of the Localization by cAMP-dependent Protein Kinase-dependent Phosphorylation*

  2004cited by this paper
• PDZ domain proteins of synapses

  2004cited by this paper
• Immunohistochemical localization of PDE10A in the rat brain.

  2003influential reference
• mRNA expression patterns of the cGMP‐hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain

  2003cited by this paper
• PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

  2003cited by this paper
• The neurochemical and behavioral effects of papaverine in vivo suggest PDE10 inhibition is “antipsychotic”

  2003cited by this paper
• Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling*

  2003cited by this paper
• Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

  2002cited by this paper
• PDZ domains and the organization of supramolecular complexes.

  2001cited by this paper
• Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

  2000cited by this paper
• Phosphodiesterases and cyclic nucleotide signaling in endocrine cells.

  2000cited by this paper
• Analysis of the Association of Proteins with Membranes

  2000cited by this paper
• The Rhesus Monkey Brain in Stereotaxic Coordinates

  1999influential reference
• Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)*

  1999cited by this paper
• Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

  1999cited by this paper
• Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade.

  1999cited by this paper
• Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase.

  1999cited by this paper
• PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization.

  1999cited by this paper
• Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A.

  1999cited by this paper
• The Synaptic Organization of the Brain, 4th edition

  1998cited by this paper
• Neostriatal cell subtypes and their functional roles.

  1997cited by this paper
• Tailoring cAMP-signalling responses through isoform multiplicity.

  1997cited by this paper
• Striatal interneurones: chemical, physiological and morphological characterization.

  1995cited by this paper
• Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95.

  1995cited by this paper
• A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain.

  1993influential reference
• Biochemical Characterization and Localization of a Non‐N‐Methyl‐D‐Aspartate Glutamate Receptor in Rat Brain

  1992influential reference
• Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles.

  1985cited by this paper
• DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• The synaptic organization of the brain: An introduction

  1974cited by this paper

• A local inhibitory plasticity rule for control of neuronal firing rate and supralinear dendritic integration

  2026cites this paper
• PDE1B and PDE10A as novel targets for schizophrenia: from molecular design and synthesis to therapeutic promise

  2026cites this paper
• PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges

  2025cites this paper
• Molecular unbalances between striosome and matrix compartments characterize the pathogenesis of Huntington’s disease model mouse

  2025cites this paper
• Inhibition of Phosphodiesterase 10A by MP‐10 Rescues Behavioral Deficits and Normalizes Microglial Morphology and Synaptic Pruning in A Mouse Model of FOXP1 Syndrome

  2025cites this paper
• Papaverine enhances autophagy, synaptic function, and memory in a mouse model of chronic REM sleep deprivation

  2025cites this paper
• Molecular Imbalances Between Striosome and Matrix Compartments Characterize the Pathogenesis and Pathophysiology of Huntington’s Disease Model Mouse

  2025cites this paper
• THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia.

  2024cites this paper
• Optimization of protocols for immunohistochemical assessment of enteric nervous system in formalin fixed human tissue

  2024cites this paper
• In the Brain of Phosphodiesterases: Potential Therapeutic Targets for Schizophrenia

  2024cites this paper
• Exploring dimethoxy naphthalenyl methoxyphenyl quinazolinyl amine as a PDE10A inhibitor: In-silico studies, synthesis and binding interactions with serum albumin

  2024cites this paper
• An integrated single-nucleus and spatial transcriptomics atlas reveals the molecular landscape of the human hippocampus

  2024cites this paper
• A novel combination treatment for fragile X syndrome predicted using computational methods

  2023cites this paper
• Cross-pathway integration of cAMP signals through cGMP and calcium-regulated phosphodiesterases in mouse striatal cholinergic interneurons

  2023cites this paper
• Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia

  2023cites this paper
• Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy

  2023cites this paper
• Easily automated radiosynthesis of [18F]P10A-1910 and its clinical translation to quantify phosphodiesterase 10A in human brain

  2022cites this paper
• Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-one as a phosphodiesterase 10A inhibitor

  2022cites this paper
• Phosphodiesterase 10A autoimmunity presenting as cerebellar ataxia responsive to plasma exchange: a case report

  2022cites this paper
• Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.

  2022cites this paper
• Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy

  2022cites this paper
• PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?

  2021cites this paper
• Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.

  2021cites this paper
• Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.

  2021cites this paper
• Transcriptional and anatomical diversity of medium spiny neurons in the primate striatum.

  2021cites this paper
• Compartmentalized Signaling in Aging and Neurodegeneration

  2021cites this paper
• Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016

  2021cites this paper
• Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination

  2021cites this paper
• A2A Receptor Dysregulation in Dystonia DYT1 Knock-Out Mice

  2021cites this paper
• Computer simulation to identify selective inhibitor for human phosphodiesterase10A

  2021cites this paper
• Phosphodiesterase 10A Is a Critical Target for Neuroprotection in a Mouse Model of Ischemic Stroke

  2021cites this paper
• Phosphodiesterase 10A Is a Mediator of Osteogenic Differentiation and Mechanotransduction in Bone Marrow-Derived Mesenchymal Stromal Cells

  2020cites this paper
• PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.

  2020cites this paper
• Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington’s Disease

  2020cites this paper
• The role of circadian rhythm in the regulation of cellular protein profiles in the brain.

  2020cites this paper
• Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.

  2020cites this paper
• Phosphodiesterase 10A Inhibition Leads to Brain Region-Specific Recovery Based on Stroke Type

  2020cites this paper
• Transcriptional Diversity of Medium Spiny Neurons in the Primate Striatum

  2020cites this paper
• Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.

  2020cites this paper
• Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression.

  2019cites this paper
• In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659.

  2019cites this paper
• Protein-Protein Interactions of Phosphodiesterases.

  2019cites this paper
• Phosphodiesterase 10A IgG

  2019cites this paper
• PET Radioligands for imaging of the PDE10A in human: current status.

  2019cites this paper
• A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects

  2019cites this paper
• Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.

  2019cites this paper
• Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.

  2019cites this paper
• Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains*

  2019cites this paper
• PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.

  2019cites this paper
• A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia.

  2019cites this paper
• Molecular Imaging in Huntington's Disease.

  2018cites this paper
• Development of 2-(2-(3-(4-([18F]Fluoromethoxy- d2)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione for Positron-Emission-Tomography Imaging of Phosphodiesterase 10A in the Brain.

  2018cites this paper
• Chapter 2 Current Understanding of PDE 10 A in the Modulation of Basal Ganglia Circuitry

  2018cites this paper
• RNA-Sequencing Analysis Revealed a Distinct Motor Cortex Transcriptome in Spontaneously Recovered Mice After Stroke

  2018cites this paper
• Imaging phosphodiesterase‐10a availability in cocaine use disorder with [11C]IMA107 and PET

  2018cites this paper
• TAK‐063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia

  2018cites this paper
• Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease

  2018cites this paper
• A mechanistic review on GNAO1-associated movement disorder.

  2018cites this paper
• In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

  2018cites this paper
• Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.

  2018cites this paper
• Huntington’s disease: novel therapeutic perspectives hanging in the balance

  2018cites this paper
• A Selective Phosphodiesterase 10A Inhibitor Reduces L‐Dopa‐Induced Dyskinesias in Parkinsonian Monkeys

  2018cites this paper
• Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

  2017cites this paper
• Potential drug targets and treatment of schizophrenia

  2017cites this paper
• Radiosynthesis and biological evaluation of the new PDE10A radioligand [18 F]AQ28A.

  2017cites this paper
• Role of Phosphodiesterases in Huntington's Disease.

  2017cites this paper
• Novel PDE10A transcript diversity in the human striatum: Insights into gene complexity, conservation and regulation.

  2017influential citation
• Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.

  2017cites this paper
• Phosphodiesterases: CNS Functions and Diseases

  2017influential citation
• Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia

  2017influential citation
• Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR

  2017cites this paper
• Phosphodiesterase Diversity and Signal Processing Within cAMP Signaling Networks.

  2017cites this paper
• Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents

  2017cites this paper
• Dopamine D1 signaling involvement in the effects of the phosphodiesterase 10A inhibitor, PDM‐042 on cognitive function and extrapyramidal side effect in rats

  2017cites this paper
• A strategy to improve the success rate of CNS drug development: TAK-063, a novel PDE10A inhibitor, as a case study.

  2017cites this paper
• The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats.

  2017cites this paper
• Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling

  2017cites this paper
• PDE Inhibitors for the Treatment of Schizophrenia.

  2017cites this paper
• Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.

  2017cites this paper
• Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

  2017cites this paper
• Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications

  2016influential citation
• Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.

  2016cites this paper
• Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats

  2016cites this paper
• Inhibition of phosphodiesterase 10 A attenuates morphine-induced conditioned place preference

  2016cites this paper
• Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

  2016cites this paper
• Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia

  2016cites this paper
• A novel thermoregulatory role for PDE10A in mouse and human adipocytes

  2016cites this paper
• TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge.

  2016cites this paper
• Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory.

  2016cites this paper
• Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder

  2016cites this paper
• TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms

  2016cites this paper
• Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

  2016cites this paper
• The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models

  2016cites this paper
• Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.

  2015cites this paper
• A disfunção dopaminérgica mesolímbica na psicose: uma revisão da literatura

  2015cites this paper
• Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.

  2015cites this paper
• AMG 580: A Novel Small Molecule Phosphodiesterase 10A (PDE10A) Positron Emission Tomography Tracer

  2015cites this paper
• The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.

  2015cites this paper
• Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject

  2015cites this paper
• Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum*

  2015cites this paper